InvestSMART

Pharmaxis Ltd (ASX: PXS) - Announcements

- Current share price for PXS : $0.027

ASX company news and announcements for Pharmaxis Ltd (PXS) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pharmaxis Ltd (PXS) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pharmaxis Ltd (PXS), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pharmaxis Ltd (PXS)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- US FDA APPROVES ARIDOL 6 Oct 2010 9:40AM $2.350 $0.027 fallen by 98.85%
- Agreement for European Marketing of Bronchitol 31 Aug 2010 8:29AM $2.030 $0.027 fallen by 98.67%
- Preliminary Final Report 12 Aug 2010 4:56PM $2.110 $0.027 fallen by 98.72%
- Appendix 4C - quarterly 21 Jul 2010 4:33PM $2.110 $0.027 fallen by 98.72%
- Results for Second Phase 3 Trial of Bronchitol in CF 22 Jun 2010 4:21PM $3.120 $0.027 fallen by 99.13%
- Trading Halt 21 Jun 2010 9:38AM $3.120 $0.027 fallen by 99.13%
- Sustained Benefit Following 18 Month Bronchitol Treatment 17 May 2010 10:00AM $3.180 $0.027 fallen by 99.15%
- Appendix 4C - quarterly March 2010 14 Apr 2010 4:39PM $3.050 $0.027 fallen by 99.11%
- Pharmaxis Announces Milestone in Phase 3 Trial for CF 14 Apr 2010 8:58AM $2.800 $0.027 fallen by 99.04%
- Pharmaxis Completes Phase II Clinical Study with ASM8 11 Mar 2010 11:04AM $2.590 $0.027 fallen by 98.96%
- Pharmaxis completes clinical trial with PXS25 9 Feb 2010 10:54AM $2.440 $0.027 fallen by 98.89%
- Half Yearly Report and Accounts 5 Feb 2010 8:56AM $2.470 $0.027 fallen by 98.91%
- Appendix 4C - Quarterly Cash Flow 27 Jan 2010 4:51PM $2.670 $0.027 fallen by 98.99%
- Pharmaxis to acquire Canadian company TOPIGEN Pharmaceutical 12 Jan 2010 10:20AM $2.770 $0.027 fallen by 99.03%
- Pharmaxis receives response letter from the FDA on Aridol 29 Dec 2009 8:44AM $2.790 $0.027 fallen by 99.03%
- Pharmaxis lodges TGA application to market Bronchitol for CF 17 Dec 2009 9:24AM $2.740 $0.027 fallen by 99.01%
- PHARMAXIS ANNOUNCES SUSTAINED BENEFIT WITH BRONCHITOL 2 Dec 2009 9:56AM $2.760 $0.027 fallen by 99.02%
- Pharmaxis Applies to Market Bronchitol for CF in Europe 29 Oct 2009 9:44AM $2.540 $0.027 fallen by 98.94%
- Commencement of Bronchiectasis Study and Aligning Strategy 23 Oct 2009 9:49AM $2.610 $0.027 fallen by 98.97%
- Appendix 4C - quarterly 14 Oct 2009 4:46PM $2.360 $0.027 fallen by 98.86%
- Second CF Trial Passes Recruitment Target 18 Sep 2009 9:15AM $2.450 $0.027 fallen by 98.90%
- Preliminary Final Report 14 Aug 2009 8:25AM $2.390 $0.027 fallen by 98.87%
- Appendix 4C - Quarterly Cash Flow 22 Jul 2009 5:13PM $2.500 $0.027 fallen by 98.92%
- Phase 3 CF Trial Results Presented at European Conference 16 Jun 2009 9:35AM $2.590 $0.027 fallen by 98.96%
- Pharmaxis Announces Placement of $47 Million and SPP 4 Jun 2009 9:42AM $2.600 $0.027 fallen by 98.96%

701 - 725 of 836 results

Page 29 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.